Microbial Products Market Research Report Information By Type (Enzymes, Polysaccharides, Nutrients, Chemotherapeutic Agents, Antibiotics, and Vaccines), By Source (Bacterial, Viral, and Fungi), By Applications (Pharmaceutical Diagnostic, and Biotechnology), By End-Users (Pharmaceutical Industries, Biotechnological Industries, Hospitals and Clinics, Diagnostic Labs, Research, and Academics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Microbial Products Market Overview

Microbial Products Market Size was valued at USD 1.59 Billion in 2023. The Microbial Products market industry is projected to grow from USD 1.69 Billion in 2024 to USD 2.58 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.44% during the forecast period (2024 - 2032). Increasing cancer patient population and increased prevalence of diseases are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

MicroHarvest, a German biotech business, has collaborated with VEGDOG, an animal-free pet food supplier, to launch the first-ever microbial protein dog treat.

The new treat will be offered on May 6 at the 2024 Pet Food Forum Europe, which will be held in Nuremberg, Germany, during Interzoo Europe.

The VEGDOG Pure Bites snack, which the business claims is a first for Europe's dog food industry, blends MicroHarvest's innovative microbial protein with potato and apple pomace. Its hypoallergenic qualities make it ideal for dogs who cannot accept standard protein sources. MicroHarvest claims that its high tolerance and digestion, as well as its excellent flavor, make it the best option for dogs with severe intolerances and allergies.

"Our goal at VEGDOG is to show dog owners that they do not have to rely on meat-based products to feed their pets," said Tessa Zaune-Figlar, VEGDOG founder and CEO. "With this modern approach and our high-quality, healthy, and delicious products, we were able to pioneer a new market." We are starting a new chapter by cooperating with our partner MicroHarvest to bring to market a potential snack that exhibits our capacity to innovate."

With global protein demand expected to increase by 50% by 2050, MicroHarvest can produce tons of high-quality microbial protein ingredients in just 24 hours, providing a highly scalable and consistent protein solution, according to the company.

"We are constantly looking for innovative protein sources that benefit both our dogs and the environment," stated Dr. Carla Steffen, VEGDOG's director of research and development. "We place a great value on developing our goods using scientific facts. MicroHarvest's microbial protein has been shown to be highly digestible, tasty, and sustainable, therefore it meets all of these criteria.

Fermented microbial proteins, like protein sources from algae, insects, and cell cultures, are more sustainable than animals since they use less land, water, feed, and other resources. Microbial proteins may use less resources than soy and other plant-based proteins.

Another is to make nitrogen-fixing microbial products for row crops available in other areas and new product concepts on the basis of having long shelf life and seed life, which was introduced in BioConsortia in February 2024.

In Wisconsin’s Oak Creek, Microbial Discovery Group continued its growth trajectory by adding a third facility in April 2024 to augment fermentation and drying capacities, thus supporting the development of sustainable microbe-based solutions.

Microbial soil inoculants were launched by ProGro BIO for home and garden enthusiasts, enhancing soil health and plant growth in May 2024.

Proventus Bioscience founders purchased Becker Microbial Products so as to be able to exploit their know-how towards innovation as well as increase the offerings of Becker’s March 2024.

Heliae Development Llc is improving upon its algae-based microbial products with respect to enhanced soil health and crop productivity during March 2024.

April 2024 saw FMC Corporation join forces with Novozymes, combining the two firms’ extensive experience to create microbial crop protection alternatives for sustainable farming.

Agrinos released a new biofertilizer in May 2024, which is expected to promote increased yields and enhanced resilience of crops by stimulating the activity of soil microorganisms.

By May 2024, Pivot Bio would have received an additional $100 million to enable it to scale its microbial nitrogen fixation technology that will minimize reliance on synthetic fertilizers.

In June 2024, Ginkgo Bioworks joined hands with Bayer to produce microbial solutions applicable to sustainable agriculture, focusing on nitrogen fixation in plants and crop disease prevention.

In June this year, Azotic Technologies developed another product based on microbes specifically for wheat that enhances nitrogen fixation and reduces our need for synthetic fertilizers.

On June 15th, Marrone Bio Innovations opened up more distribution channels for Marrone’s microbial pesticides so as to increase market penetration and improve crop protection.

Bioconsortia’s novel microbial inoculant was registered by July 2024; this makes it possible to improve yields while also boosting soil health.

AgroFresh Solutions entered into a partnership with BioTrove to create and sell bacteria-based commodities that prolong the shelf lives of fresh vegetables since 2024.

Starting in July 2024, Symborg will launch its product lines based on microorganisms into additional territories worldwide designed to raise global agricultural productivity.

Microbial Products Market Trends

• Growing awareness of the value of microbe-based goods is driving the market growth

Market CAGR for microbial products is driven by the significant increase in awareness worldwide. Human illness diagnosis is the primary use of microbial identification. It provides trustworthy findings in a short period, which aids in the timely implementation of therapeutic options. Particularly useful in regions with insufficient healthcare infrastructure, microbial identification products can aid in controlling infectious diseases. Furthermore, the rising incidence of serious diseases like cancer will spur business development in the next years. The production of enzymes for end-use industries like food preservation, leather, and paper is also anticipated to fuel the market's growth over the next few years.

Additionally, the increasing need for microbiological diagnostics. Natural compounds from microbes have had far-reaching effects on human, plant, and animal life, making them a prospective source. More studies show the positive effects of using natural chemicals produced by microorganisms in these industries. Primary metabolites such as amino acids, enzymes, vitamins, organic acids, and alcohol are used in the food and beverage industry and the biotransformation of raw materials. The majority of microorganisms' organic components come from plant or tissue extraction. The biopharmaceutical industry relies heavily on them because of their proven effectiveness in reducing infectious disease prevalence in humans and animals. Nevertheless, there are obstacles, such as the need to keep large numbers of active bacteria on seeds throughout the seed treatment process and the need for technological advances in microbial inoculants. The need to feed a burgeoning  population that is expanding exponentially, the desire for ecologically friendly agricultural practises, and the general public's growing awareness about environmental safety are some of the main drivers of the agricultural microbial sector.

For instance, topline results from the Phase 3 EMBARK trial of XTANDI® (enzalutamide) in men with high-risk biochemical recurrence (BCR) of non-metastatic hormone-sensitive prostate cancer (nmHSPC, also called non-metastatic castration-sensitive prostate cancer or nmCSPC) were announced by Pfizer Inc. and Astellas Pharma Inc. As a result, the demand for microbial products is anticipated to increase throughout the projection period due to rising awareness. Thus, the driving factor is microbial products market revenue.

Microbial Products Market Segment Insights

Microbial Products Type Insights

The  microbial products market segmentation, based on type, includes enzymes, polysaccharides, nutrients, chemotherapeutic agents, antibiotics, and vaccines. In 2022, the enzymes segment led the microbial products market in revenue because it speeds up the digestive and absorption processes, which may help people consume fewer calories and shed excess weight.

Microbial Products Source Insights

The  microbial products market segmentation, based on source, includes bacterial, viral, and fungi. The bacterial segment is expected to develop at a CAGR of 6.20% over the projected period, making up the largest market share due to the extremophile strains collected from a wide range of environments, microbial genomic DNA from strains that possibly enhanced by the use of the polymerase chain reaction (PCR) technique, methicillin-resistant and -sensitive research materials, quality control organisms for commercial identification systems, and bacterial cultures are all routinely used in laboratories and manufacturing settings.

Figure 1  Microbial Products Market by Source, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Microbial Products Application Insights

The  microbial products market segmentation, based on application, includes pharmaceutical, diagnostic, and biotechnology. The segment with the largest market share in biotechnology is expected to grow fastest at a CAGR of 6.20% over the next several years due to the factors that can be traced back to the sophisticated engineering employed in biotechnology to increase the production of microbial products by means such as the introduction of mutations into an organism and the amplification of genes with plasmids.

Microbial Products End-Users Insights

The  microbial products market segmentation, based on end-users, includes pharmaceutical industries, biotechnological industries, hospitals & clinics, diagnostic labs, research, and academics. The hospitals & clinics' top seller is expected to grow fastest at a CAGR of 6.20% in the future because of a rise in disorder incidence.

 Microbial Products Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American microbial products market will dominate due to technological progress, and the rate at which regulators approve identical candidates is rising.

Further, the major countries studied in the market report are The US, Canada, German, France, the U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  Microbial Products Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s microbial products market accounts for the second-largest market share because of the increasing occurrence of novel infectious diseases and the significance of clinical goods based on microbes. Further, the German microbial products market held the largest market share, and the UK microbial products market was the fastest-growing market in the European region.

The Asia-Pacific microbial products market is expected to grow at the fastest CAGR from 2024 to 2032 due to an increase in the need for everything from immunizations to amino acids and population growth. In addition, the rising government awareness in the region has increased the need for clinical labs. Moreover, China’s microbial products market held the largest market share, and the Indian microbial products market was the fastest-growing market in the Asia-Pacific region.

Microbial Products Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the microbial products market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the microbial products industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the  microbial products industry to benefit clients and increase the market sector. In recent years, the microbial products industry has offered some of the most significant technological advancements. Major players in the microbial products market, including Amgen Inc., Merck & Co. Inc., VALENT Biosciences Corp., GlaxoSmithKline plc., Pfizer Inc., BIOMÉRIEUX SA, Ajinomoto Co. Inc., SANOFI S.A, Novartis AG, NOVADIGM Therapeutics, Kyowa Hakko Bio Co. Ltd., and others, are attempting to increase market demand by investing in research and development operations.

Amgen's mission is to find, create, manufacture, and distribute novel human medicines to benefit patients with life-threatening illnesses. Part of the plan is to use cutting-edge human genetics and others. Amgen employs its expertise to target areas with significant medical needs and to develop treatments that drastically enhance patients' quality of life. 

Amgen has been a leader in the biotechnology industry since its founding in 1980. The company has treated millions of patients worldwide and is working on several innovative medications that could revolutionize the industry. Amgen is included in the Dow Jones Industrial Average and the Nasdaq-100 indices. Amgen was designated one of Forbes' "World's Best Employers" and one of Barron's "America's 100 Most Sustainable Companies" in 2022. In May 2023, Amgen and TScan Therapeutics, Inc. established a multi-year agreement to identify the antigens identified by T cells in Crohn's disease patients using TScan's unique target identification technology, TargetScan.

Merck, or MSD outside of North America, has one common goal to save and improve people's lives worldwide by applying cutting-edge research. We have given people a reason to believe in the future for more than 130 years, thanks to the creation of life-saving medicines and vaccinations. Today, we are at the vanguard of research to bring you innovative health solutions that improve the treatment and prevention of illness in humans and other animals. Tomorrow, we hope to be the world's preeminent research-intensive biopharmaceutical firm. Every day, we fight to create a secure future that is both sustainable and healthy for all communities and individuals worldwide by cultivating a diverse and inclusive  workforce and acting ethically. 

In April 2023, Moderna, Inc., the world's leading developer of messenger RNA (mRNA) therapeutics and vaccines, Merck, or MSD in other parts of the world, presented the first detailed results from their Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti- I. 

Key Companies in the Microbial Products Market include

• Amgen Inc.


• Merck & Co. Inc.


• VALENT Biosciences Corp.


• GlaxoSmithKline plc.


• Pfizer Inc.


• BIOMÉRIEUX SA


• Ajinomoto Co. Inc.


• SANOFI S.A


• Novartis AG


• NOVADIGM Therapeutics


• Kyowa Hakko Bio Co.

Microbial Products Industry Developments

April 2023: Amgen collaborators at the Association of Black Cardiologists (ABC) and Morehouse School of Medicine (MSM) have started the African American Heart Study to evaluate the association between Lp (a) and atherosclerotic cardiovascular disease (ASCVD). Five thousand African Americans from the United States will participate in the study. Atherosclerotic cardiovascular disease (ASCVD) involves cardiac arrest and cerebrovascular accident, both caused by cholesterol plaque in the arteries.

March 2023: GSK plc and SCYNEXIS, Inc. have purchased the rights to commercialize Brexafemme worldwide. The FDA has approved Brexafemme (ibrexafungerp tablets) to treat and prevent vulvovaginal candidiasis (VVC) in the United States. 

Microbial Products Market Segmentation

Microbial Products Type Outlook

• Enzymes


• Polysaccharides


• Nutrients


• Chemotherapeutic Agents


• Antibiotics


• Vaccines

Microbial Products Source Outlook

• Bacterial


• Viral


• Fungi

Microbial Products Applications Outlook

• Pharmaceutical


• Diagnostic


• Biotechnology

Microbial Products End-Users Outlook

• Pharmaceutical Industries


• Biotechnological Industries


• Hospitals and Clinics


• Diagnostic Labs


• Research


• Academics

Microbial Products Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America